Results 101 to 110 of about 11,456 (188)

Improved Glucagon Sensitivity Following Weight Loss: A Systematic Review and Meta‐Analysis

Obesity Reviews, EarlyView.
ABSTRACT Objective This systematic review and meta‐analysis investigated the effect of weight loss in people with obesity on two biomarkers of glucagon resistance: fasting plasma glucagon and alanine. Methods A comprehensive search was conducted in Medline and Embase. Random‐effects meta‐analyses and correlation analyses were performed.
Hye‐Rin Charlotte Kim, Lima Hamidi, Anne Majumdar, Matyas Fehervari, Emma Rose McGlone   +4 more
wiley   +1 more source

Renoprotective Effects of Canagliflozin in Db/db Diabetic Mice

, 2019
Diabetes is one of the major causes of chronic kidney disease which could lead to end-stage renal disease. Previously, we have shown increased urinary angiotensin converting enzyme 2 (ACE2) and neprilysin (NEP) in db/db mouse model of type 2 diabetes ...
Dhakal, Sanjeev, Hosawi, Anhar, Thanekar, Unmesha, Elased, Khalid M., Gill, Rupinder K   +4 more
core   +1 more source

Direct Regioselective para‐Fluorination via I(I)/I(III) Catalysis

Angewandte Chemie, Volume 138, Issue 37, 7 September 2026.
A direct, para‐selective fluorination by I(I)/I(III) catalysis is disclosed that does not require substrate pre‐functionalization. This strategy leverages the Leonard link inherent to phenylpropanoate and phenylpropanamides to promote a spirocyclization/para‐selective sequence. The C3‐side chain maps onto a range of common drug scaffolds and allows the
Christoph Roblick, Julian D. Bendix, Timothy A. Hilton, Kathrin Bussmann, Constantin G. Daniliuc, Ryan Gilmour   +5 more
wiley   +2 more sources

Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

Diabetology & Metabolic Syndrome, 2017
Background It is unknown whether canagliflozin, a selective sodium glucose co-transporter 2 inhibitor, reduces epicardial adipose tissue (EAT) thickness, which is associated with insulin resistance and is a risk factor for coronary artery disease ...
Shusuke Yagi, Yukina Hirata, Takayuki Ise, Kenya Kusunose, Hirotsugu Yamada, Daiju Fukuda, Hotimah Masdan Salim, Gulinu Maimaituxun, Susumu Nishio, Yuriko Takagawa, Saori Hama, Tomomi Matsuura, Koji Yamaguchi, Takeshi Tobiume, Takeshi Soeki, Tetsuzo Wakatsuki, Ken-ichi Aihara, Masashi Akaike, Michio Shimabukuro, Masataka Sata   +19 more
doaj   +1 more source

Sodium–glucose cotransporter 2 inhibitors for hypertension in cardiovascular–kidney–metabolic syndrome

Experimental Physiology, EarlyView.
Abstract The antihypertensive mechanism of sodium–glucose cotransporter 2 (SGLT2) inhibitors has been traditionally attributed to osmotic diuresis. However, emerging evidence reveals multifaceted mechanisms beyond diuresis, including regulation of the renin–angiotensin–aldosterone system, sympathetic nervous system suppression, ion homeostasis ...
Chunxiang Xu, Xingyu Qiu, Nan Xu, Gensheng Zhang, Enyin Lai, Liang Zhao   +5 more
wiley   +1 more source

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes

, 2017
Joseph A Messana,1 Stanley S Schwartz,2,3 Raymond R Townsend1 1Nephrology Division, Perelman School of Medicine, University of Pennsylvania, 2Main Line Health, 3Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA Abstract: Caring ...
Messana JA, Townsend RR, Schwartz SS
core  

Adaptations of glucagon‐like peptide‐1 receptor agonist‐induced weight loss, drivers of weight regain and future directions of therapeutics

The Journal of Physiology, EarlyView.
Abstract figure legend During GLP‐1RA treatment reduced appetite and energy intake, delayed gastric emptying, decreased visceral fat mass and improved glycaemic control contribute to weight loss. After treatment cessation these benefits are partially or completely reversed, resulting in weight regain, accompanied by increased appetite and energy intake,
Camille E. M. Piguet, Rosie Nucci, Jacqueline L. Beaudry   +2 more
wiley   +1 more source

Canagliflozin ameliorates high-salt-induced renal injury and premature aging in male Dahl salt-sensitive rats, with associated changes in SIRT6/HIF-1α signaling

Renal Failure
Sodium–glucose cotransporter 2 inhibitors (SGLT2is) exhibit renoprotective effects in diabetic and nondiabetic patients; however, the underlying mechanism remains unclear.
Qiuyan Wang, Yi Liang, Qingjuan Zuo, Lili He, Tingting Zhang, Zhongli Wang, Jianlong Zhai, Boce Cao, Sai Ma, Guorui Zhang, Fan Lu, Yifang Guo   +11 more
doaj   +1 more source

Canagliflozin Mitigates Diabetic Cardiomyopathy through Enhanced PINK1-Parkin Mitophagy

Diabetic cardiomyopathy (DCM) is a major determinant of mortality in diabetic populations, and the potential strategies are insufficient. Canagliflozin has emerged as a potential cardioprotective agent in diabetes, yet its underlying molecular mechanisms
Jieying Liu, Chunru Yang, Zerui Ding, Xiaojun Zhai, Miao Yu, Cheng Xiao   +5 more
core   +1 more source

SGLT2i in heart failure: Cardiorenal mechanisms, clinical evidence and translational perspectives

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
SGLT2 inhibitors improve heart failure outcomes through integrated cardiorenal mechanisms. In the kidney, they reduce glucose and sodium reabsorption, promoting natriuresis, osmotic diuresis and renal protection. In the heart, they enhance myocardial energetics, reduce inflammation, oxidative stress, fibrosis and adverse remodelling, resulting in fewer
Jelica Grujic‐Milanovic, Jovana Rajkovic, Radmila Novakovic, Javad Sharifi‐Rad, Daniela Calina   +4 more
wiley   +1 more source